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Abstract: Prostate cancer is one of the most commonly diagnosed cancers in men and almost half of male cancer survi-
vors in the US have had a prostate cancer diagnosis. Insomnia is common among cancer patients and survivors. There is 
evidence that cognitive behavioural therapy can be used to effectively manage insomnia among women with breast 
cancer. The aim of this review was to investigate the prevalence, risk factors and management of insomnia among men 
with prostate cancer. The effect of insomnia on the psychological health and health-related quality of life of these pa-
tients and/or survivors is also discussed. Increased awareness and knowledge of this symptom among men with prostate 
cancer may facilitate improved diagnosis, and management of insomnia in this large population. This in turn may im-
prove the health-related quality of life of these men. Therefore, research into the effective management of insomnia 
among men with prostate cancer is essential. 
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Introduction 
Prostate cancer is the most commonly diagnosed cancer 
among men in Western countries. There will be an esti-
mated 1.7 million incidences of prostate cancer global-
ly by 2030
[1]
. The number of survivors is also rising, with 
43% of male cancer survivors in the US having had a 
prostate cancer diagnosis
[2]
. Currently the 10- and 15-year 
relative survival of men with prostate cancer in the US is 
more than 90%
[2]
. These trends are attributed to the 
widespread use of prostate specific antigen (PSA) testing, 
which has resulted in men being diagnosed with prostate 
cancer at a younger age, and with less advanced dis-
ease
[3-4]
, ageing populations and improved survival
[5-7]
. 
There is no consensus on the optimum treatment of 
men with localised disease
[8,9]
. Radical prostatectomy 
and radiotherapy are the most commonly used treatments 
for localised prostate cancer; active surveillance or 
watchful waiting are appropriate management strategies 
in some cases, and brachytherapy is becoming more 
common. Androgen deprivation therapy (ADT) is fre-
quently used as a neo-adjuvant or adjuvant treatment, 
and as a primary treatment for older men and those with 
recurrent or more advanced cancer. Each treatment car-
ries the potential for general and disease-specific adverse 
effects or symptoms, which can be acute or chronic, 
lasting throughout survivorship
[3,10,11]
. These symptoms 
can negatively affect the global health-related quality of 
life (HRQoL) of men with prostate cancer
[3,8,10,12]
 and are 
associated with increased risks of depression, anxiety 
and distress among survivors
[20]
. Much of the focus 
has been on the physical disease-specific symptoms in-
cluding urinary incontinence, sexual dysfunction 
and bowel problems experienced by men with prostate 
cancer, while more general symptoms including insom-
nia have received less attention in this patient 
group
[3,8,10,11,14]
. 
Insomnia or sleep disturbance is a common symptom, 
Drummond FJ 
 75 
doi: 10.18282/amor.v2.i2.94  
which affects cancer patients
[21,29]
. Insomnia is defined as 
difficulty initiating and/or maintaining sleep, or 
non-restorative sleep, lasting for at least one month and 
resulting in clinically significant daytime impairment or 
distress
[30]
. Insomnia often goes unrecognised, it can be 
poorly managed and has negative effects on the HRQoL 
of cancer patients
[29,31,32]
. The aim of this review was to 
investigate the prevalence, risk factors and management 
of insomnia among men with prostate cancer. 
Methods 
A search on PubMed was conducted using the terms 
(“sleep initiation and maintenance disorders” OR “sle-
ep”[All Fields] AND “initiation”[All Fields] AND 
“maintenance”[All Fields] AND “disorders”[All Fields]) 
OR “sleep initiation and maintenance disorders”[All 
Fields] OR “insomnia”[All Fields] AND (“prostatic neo-
plasms” OR (“prostatic”[All Fields] AND “neo-
plasms”[All Fields]) OR “prostatic neoplasms”[All 
Fields] OR (“prostate”[All Fields] AND “cancer”[All 
Fields]) OR “prostate cancer”[All Fields]). 
Findings from multi-cancer site studies, which in-
cluded men with prostate cancer, were used if they pre-
sented prostate cancer-specific information
[21,22,24-26]
. Ho-
wever, studies that gave only the overall findings were 
excluded
[23,27,28]
. 
Results 
Methodologies to assess insomnia among 
men with prostate cancer 
There is no optimum method to measure or assess in-
somnia or sleep disturbances. Both subjective measure-
ments (e.g., questionnaires and sleep diaries) and object-
tive measurements (e.g., wrist actigraphy) have been 
employed to assess insomnia among men with prostate 
cancer. 
The questionnaires most commonly used to measure 
insomnia include the Insomnia Severity Index (ISI), the 
Pittsburgh Sleep Quality Index (PSQI), the General Sleep 
Disturbance Scale (GSDS), the Athens Insomnia Scale 
(AIS) and the Medical Outcomes Study (MOS) Sleep 
Scale, all of which assess various aspects of sleep over a 
period of between one week and one month prior to the 
completion of the questionnaire
[33-37]
. A number of 
HRQoL instruments also assess sleep disturbances or 
insomnia as one of a number of possible symptoms ex-
perienced by people with cancer. One of the most com-
monly used is the European Organisation for Research 
and Treatment of Cancer (EORTC) QLQ-C30 which asks, 
during the past week ‘Have you had trouble sleep-
ing?’[38]. The Insomnia Diagnostic Interview[39] and sleep 
diaries, as a repeated measure of sleeping patterns and 
habits, have also been used as subjective measures of 
insomnia
[40]
. The most common objective measurement 
of insomnia among men with prostate cancer is the wrist 
actigraphy, which measures sleep-wake circadian activity 
rhythms by recording movements to estimate a number 
of sleep parameters, including the total sleep time and 
number of nocturnal awakenings in a research environ-
ment or in the patient’s own sleeping environment[41]. 
Prevalence of insomnia among men with 
prostate cancer 
Insomnia or sleep disturbances among men with prostate 
cancer has been investigated in both cross-sectional and 
longitudinal studies (Table 1)
[8,14,15,17,18,21,24,25,42-48]
. 
Within cross-sectional studies, between 8% and 53% of 
men with prostate cancer were reported to experience 
insomnia
[15,17,18,21,42-44]
. Difficulties with both initiating 
and maintaining sleep have been described
[42,44]
. 
One of the largest cross-sectional studies described that 
the prevalence of clinical levels of insomnia was 32% 
among 861 men with localised prostate cancer, who 
were between 24 and 37 months post-treatment with ra-
diotherapy, brachytherapy or radical prostatectomy
[43]
. 
Another study reported that almost one-third of 327 
prostate cancer survivors (32%) also experienced insom-
nia between 4 and 10 years post-radical prostatectomy
[42]
. 
Both of these studies used the ISI to measure sleeping 
difficulties. One of the first studies to investigate the 
effects of prostate cancer on the HRQoL of men found 
that a similar proportion of the 172 men with prostate 
cancer investigated (i.e., 29%) experienced insomnia as 
measured using the EORTC-QLQ-C30
[17]
. 
Davidson et al. observed lower rates, with 18% of 155 
men attending genitourinary clinics (141 of whom had 
prostate cancer) having insomnia (including men who 
reported difficulty sleeping in at least 7 of the previous 
28 nights) and consequent negative effects on daytime 
functioning, as measured by a Sleep Survey
[21]
. These 
men were approximately 4 years post-diagnosis and 
one-third were currently receiving treatment. The lowest 
prevalence of insomnia was reported by Lilleby et al., in 
1999; among 303 men in Norway, who were 1–10 years 
post-treatment, the prevalence of sleeping difficulties 
were 15%, 13% and 8% among men treated with radical 
prostatectomy, radiotherapy and watchful waiting, re-
spectively
[18]
.   
The highest prevalence of clinically significant in-
somnia among men with prostate cancer was 53%, ob- 
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Table 1. Prevalence of insomnia among men with prostate cancer 
Year Author Country 
Insomnia  
assessment  
instrument 
Study design Patients Findings/Comment 
2013 Bill-Axelson A 
et al.[8] 
Sweden Survey ques-
tions: During the 
past 6 months, 
(i) Have you 
had difficulty 
in sleeping at 
night? 
(ii) Have you 
taken sleeping 
pills? 
Longitudinal: 
diagnosis to 8 
years 
post-treatment 
272 men with non-metastatic 
prostate cancer randomised 
to receive radical prostatec-
tomy (N = 136) or watchful 
waiting (N = 136); 
Mean age 64 years 
 Insomnia was consistently reported 
at 30%–40% in both treatment 
groups over 8-year follow-up 
2002 Davidson JR  
et al.[21] 
 
Canada Sleep survey  
questionnaire 
Cross- 
sectional 
982 patients with cancer at 
mixed sites, of whom 141 
had prostate cancer 
 18.1% of men with prostate cancer 
reported insomnia, and 14.8% 
were taking sleep medication. 
 Overall, initiation of insomnia 
coincided with cancer diagnosis in 
48% of the cases and was chronic 
(>6 months) for 75% of cancer pa-
tients. 
 Those who were fatigued were 2.5 
times more likely to have insomnia 
than others. 
2009 Dirksen SR  
et al.[44] 
 
 
USA Insomnia  
Severity  
Index[34] 
Cross- 
sectional 
51 prostate cancer patients 
currently undergoing treat-
ment; 
Mean age of 74 years, 51% 
had stage IV prostate cancer 
 
 
 53% had clinically significant 
insomnia; 45% had difficulty initi-
ating sleep and 55% maintaining 
sleep; 37% had problems with both 
initiating and maintaining sleep. 
 Correlation was identified between 
radiation therapy and insomnia 
severity (r = 0.31, p = 0.03) and 
depression (r = 0.37, p = 0.01). 
2005 Hervouet S  
et al.[43] 
Canada Insomnia  
Severity 
Index[34] 
Cross- 
sectional 
861 men with prostate can-
cer, 24–37 months post- 
treatment, treated with radi-
cal prostatectomy (N = 
281), brachytherapy (N = 
188) or radiotherapy (N = 
392); 
Mean age = 68 years 
 31.9% had clinical levels of in-
somnia. 
 Prevalence of insomnia was high-
est post-radiotherapy (35%),   
intermediate at post-radical pros-
tatectomy (30%) and lowest post- 
brachytherapy (29%). 
 Differences by treatment were not 
statistically significant. 
2005 Jønler M    
et al.[15] 
Scandina-
vian Pros-
tate Cancer 
Group 5 
(SPCG-5) 
study 
EORTC 
QLQ-C30[39] 
Cross- 
sectional 
917 untreated patients with 
metastatic prostate cancer; 
Mean age = 72.5 years 
 20% experienced insomnia. 
 Insomnia was the third highest 
(worst) symptom score after fa-
tigue and pain. 
1994 Kornblith AB  
et al.[17] 
USA EORTC 
QLQ-C30[39] 
Cross- 
sectional 
172 prostate cancer patients 
and 83 spouses or partners; 
55% treated with ADT, 28% 
with radical prostatectomy 
and/or radiotherapy only, 
18% had not been placed on 
any treatment 
 29% and 37% of patients and 
spouses, respectively, reported 
sleep disturbances. 
 Insomnia was not associated with 
HRQoL of patients or survivors. 
Pain, fatigue and urinary problems 
did affect patients’ HRQoL. 
1999 Lilleby W  
et al.[18] 
Norway EORTC 
QLQ-C30[39] 
Cross- 
sectional 
Men with localised prostate 
cancer who had undergone 
radiotherapy (N = 154) and 
radical prostatectomy (N = 
108) or men undergoing 
watchful waiting (N = 41) at 
least one year post-treatment 
 15%, 13% and 8% of patients 
treated with radical prostatectomy, 
radiotherapy and watchful waiting, 
respectively, reported sleep diffi-
culties. 
(to be continued on the next page) 
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(Continued) 
Year Author Country 
Insomnia  
assessment  
instrument 
Study design Patients 
Findings/Comment 
2011 
(b) 
 
Miaskowski C 
et al.[49] 
 
 
 
 
 
 
 USA Pittsburgh Sleep  
Quality Index 
(PSQI) at base-
line[35]. 
General Sleep 
Disturbance 
Scale (GSDS)[36] 
administered at 
each time point. 
Longitudinal: 
at simulation 
visit, every 
other week for 
6 weeks dur-
ing treatment 
and 4 months 
post-treatment 
82 patients with 
non-metastatic prostate can-
cer who underwent primary 
or adjuvant radiotherapy;  
Mean age = 67 years; 
51% received ADT prior to 
the initiation of radiotherapy, 
10% had radical prostatec-
tomy prior to radiotherapy, 
9.8% also had brachytherapy 
 24.4% displayed sleep disturbances 
on the GSDS at the simulation visit. 
 Self-reported sleep disturbance 
increased during radiotherapy spe-
cifically from weeks 1–9, and de-
creased following completion of 
radiotherapy. Inter-individual dif-
ferences existed in the sleep trajec-
tories. However, inter-individual 
differences existed in the sleep tra-
jectories. None of the incremental 
increases in sleep disturbances 
reached clinical significance (i.e., 
score ≥43) during the study. Pre-
dictors of higher levels of sleep 
disturbance included younger age, 
higher levels of trait anxiety and 
depressive symptoms and higher 
levels of sleep disturbance at the in-
itiation of radiotherapy.  
2005 Savard J  
et al.[42] 
 Canada 
 
Insomnia  
Severity  
Index[34] 
Cross- 
sectional 
327 men with prostate cancer 
treated with radical prosta-
tectomy between 4 and 10 
years previously; 
37% had surgery only or a 
combination of treatments 
(ADT 29%, ADT + radio-
therapy 29%, radiotherapy 
5%); 
Mean age = 66 years 
 
 31.5% of the patients reported 
non-speciﬁc sleep diﬃculties 
20.5% (CI 95%, 16.3%–25.3%) 
reported taking sleep-promoting 
substance in the past month.  
 18% met speciﬁc criteria for in-
somnia. Of those, 14% had trouble 
initiating sleep only, 34% had dif-
ficulty maintaining sleep and 52% 
had a mixed difficulty of initiating 
and maintaining sleep at least 3 
nights per week; median duration of 
sleep difficulties was 59 months for 
95%. 5% had sub-acute insomnia 
(1–6 months). 
 In most of these latter cases (95%), 
insomnia was chronic (duration of 6 
months or more). Nearly half of the 
patients with insomnia reported the 
onset of their sleep diﬃculties fol-
lowing their cancer diagnosis. A 
similar proportion had no comorbid 
clinical levels of anxiety or depres-
sion. Risk factors for the presence 
of insomnia included a younger 
age, poor prognosis, presence of 
intestinal pain, depression and an-
drogen blockade-related symptoms. 
2009 Savard J  
et al.[24] 
Canada 
 
Insomnia diag-
nostic inter-
view[33] 
Longitudinal: 
perioperative 
phase (T1) and 
two months 
later (T2) 
991 patients with 
non-metastatic cancer at 
mixed sites, scheduled to 
receive curative surgery; 
269 patients (27%) had pros-
tate cancer 
 
 
 Prevalence of insomnia (syndrome 
and symptoms) among men with 
prostate cancer at T1 and T2 were 
37.8% and 27.8%, respectively. 
 Prevalence of insomnia syndrome 
alone at T1 and T2 was 15.8% and 
15.9% respectively among men 
with prostate cancer. 
 The highest rates of insomnia were 
found in breast cancer patients and 
the lowest rates were observed in 
prostate cancer patients.  
 
 
 
(to be continued on the next page) 
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(Continued) 
Year Author Country 
Insomnia  
assessment  
instrument 
Study design Patients 
Findings/Comment 
2011 Savard J 
et al.[25] 
Canada Insomnia  
diagnostic  
interview[33] 
Longitudinal: 
perioperative 
phase (T1), 2 
(T2), 6 (T3), 
10 (T4), 14 
(T5) and 18 
(T6) months 
post-surgery 
962 patients with 
non-metastatic cancer at 
mixed sites, scheduled to 
receive curative surgery; 
235 patients (24%) had 
prostate cancer 
 Prevalence of insomnia among men 
with prostate cancer was between 
36% (T1) and 25% (T6). 
 15% (N = 36) of men had their first 
episode of insomnia during the 
study. 29% (N = 68) of men had 
insomnia, which was persistent for 
at least two consecutive time points; 
36% (N = 84) had a remission from 
insomnia (for 29.8% the remission 
only lasted for one time interval); 
13% (N = 30) had a relapse during 
the course of the study. 
 Prevalence of insomnia syndrome 
was quite constant throughout the 
study with between 12% and 15% 
of men with PCa experiencing in-
somnia syndrome. 
2013 Savard J 
et al.[47] 
Canada Insomnia  
Severity 
Index[34] 
Longitudinal: 
prior to treat-
ment 
(T1, baseline); 
at 1, 2, 4, 6, 8, 
12 and 16 
months 
post-surgery 
60 men with non-metastatic 
prostate cancer scheduled to 
receive radiotherapy with 
ADT (N = 28) or without 
ADT (N = 32) 
 
 
 Insomnia scores were highest for 
those treated with ADT at baseline, 
14% in the radiotherapy and 22% in 
the ADT-radiotherapy groups had a 
clinical score for insomnia. 
 Insomnia scores in men treated with 
ADT-radiotherapy increased 
throughout treatment. Differential 
effects of short- and long-term ADT 
use were observed. Insomnia scores 
increased from baseline to 6 months 
in long-term ADT users but began 
to decrease at 6 months in 
short-term ADT users. Effects of 
ADT on insomnia were mediated by 
frequent hot flashes and night 
sweats. The authors suggested a 
transient effect of ADT on insom-
nia; that men can adapt to the nega-
tive effect of ADT on sleep. Scores 
for insomnia were relatively low in 
radiotherapy patients (14% to 22%). 
Relationship between radiotherapy 
and insomnia was mediated most 
strongly by excessive urinary fre-
quency. 
2015 Savard J 
et al.[48] 
Canada Insomnia  
Severity  
Index[34] 
Longitudinal, 
population- 
based epide-
miological 
study 
263 men with prostate 
cancer followed from base-
line to 18 months 
post-recruitment 
 ADT was related to increased in-
somnia, mediated through somatic 
symptoms, in particular night 
sweats. The highest ISI scores cor-
responded to the peak exposure to 
ADT. 
2012 Zucca AC  
et al.[26] 
Australia EORTC 
QLQ-C30[39] 
Cross- 
sectional 
863 long-term survivors, 5 
to 6 years post-diagnosis 
with cancer at mixed sites; 
133 (15%) had prostate 
cancer 
 13.4% of men with prostate cancer 
had insomnia symptoms; lower than 
those with breast, lym-
pho-hematopoietic, thyroid and 
other endocrine, head and neck, and 
lung cancer patients; higher than 
those with melanoma, colorectal, 
gynaecological and urogenital can-
cer. 
 20.2% of men with prostate cancer 
experienced two or more symptoms. 
*ADT: Androgen deprivation therapy; European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 
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served in a small study of older men (N = 51) with a 
mean age of 74 years
[44]
. More than half of these men 
(51%) had stage IV metastatic disease and they had re-
ceived a range of treatments. In contrast, of 917 older 
men (mean age 72.5 years) with untreated metastatic 
prostate cancer, who took part in the Scandinavian Pros-
tate Cancer Group study, 20% experienced insomnia
[15]
. 
Several studies used objective measures to assess in-
somnia among men with prostate cancer
[27,45]
. Hanisch et 
al. found that the total sleep time of 60 prostate cancer 
patients undergoing ADT was 5.9 h and the sleep effi-
ciency, i.e. the ratio of time asleep to the time in bed, 
was 75% as measured by wrist actigraphy
[45]
. Miaskow-
ski et al. reported that approximately 30% of cancer pa-
tients (N = 185) at mixed sites (44% with prostate cancer) 
did not sleep well as defined by a sleep efficacy of <80%. 
However, specific results of men with prostate cancer 
were not reported
[27]
. Both studies found poor concord-
ance between actigraphy measures and subjective 
measures of sleep
[27,45]
. 
Prevalence of insomnia syndrome among 
men with prostate cancer 
One cross-sectional study reported that 18% of prostate 
cancer survivors (up to 10 years post-radical prostatec-
tomy) suffered from the more serious condition, that is 
insomnia syndrome
[42]
. Insomnia syndrome was de-
fined by the authors as: (a) diﬃculty initiating (i.e., 30 
min or more to fall asleep) or maintaining sleep (i.e., 30 
min or more of nocturnal awakenings); (b) these difficul-
ties occur at least three nights per week; and (c) sleep 
disturbance causing signiﬁcant daytime impairment (e.g., 
fatigue, mood disturbances) or marked distress in the 
month prior to questionnaire completion. 
Changes in the prevalence of insomnia 
among prostate cancer patients throughout 
the disease trajectory 
Longitudinal studies reported changes in the prevalence 
of insomnia throughout the disease trajectory, from can-
cer diagnosis to the period during which men with pros-
tate cancer underwent treatment(s) and post-treat-
ment
[8,24,25,47-50]
.  
Among 269 men with non-metastatic prostate cancer 
scheduled to receive radical prostatectomy, the highest 
prevalence of insomnia was in the time between receiv-
ing a prostate cancer diagnosis and having surgery, when 
38% of men had insomnia, as assessed by an Insomnia 
Diagnostic Interview
[24]
. Prevalence of insomnia de-
creased throughout the study to 25% at 18 months post- 
diagnosis
[25]
. Of these, approximately 15% experienced 
insomnia syndrome, and rates of insomnia syndrome 
were relatively stable throughout the 18 months fol-
low-up study
[24,25]
.   
The authors identified a number of different sleep tra-
jectories throughout the cancer care pathway. Among 
prostate cancer patients who were good sleepers at diag-
nosis, between 87% (14 months post-recruitment) and  
93% (18 months post-recruitment) remained good sleep-
ers; for those who had insomnia symptoms at diagno-
sis, between 18% (2 months post-recruitment) and 44% 
(18 months post-recruitment) continued to have insomnia 
symptoms; and of those who had insomnia syndrome at 
diagnosis, between 64% (6 months post-recruitment) and 
87% (14 months post-recruitment) continued to experi-
ence insomnia syndrome
[24,25]
. However, sleep trajecto-
ries were individual and men frequently alternated betw-
een sleeping states during the study, experiencing both 
insomnia remission and relapses between time points. 
Overall, the rates of insomnia persistence, remission and 
relapse among men with non-metastatic prostate cancer 
was 29%, 36% and 13% respectively during the first 18 
months of the cancer trajectory post-surgery. 
Similarly, insomnia was found to increase during ra-
diotherapy and to decline upon treatment completion and 
up to 4 months post-treatment
[49,50]
. Miaskowski et al. 
observed that among 82 men who received either prima-
ry or adjuvant radiotherapy for non-metastatic prostate 
cancer, 24% experienced insomnia prior to treatment 
initiation
[49]
. Again, considerable inter-individual differ-
ences in sleep trajectories were observed throughout the 
study period.   
However, it is not uncommon for men to receive more 
than one treatment modality, for example, neo-adjuvant 
or adjuvant ADT and radiotherapy. One group attempted 
to dissect the discrete effects of individual treatments and 
treatment combinations on insomnia
[47,48]
. Among 60 
men with non-metastatic diseases treated with radiother-
apy or ADT with radiotherapy, the prevalence of insom-
nia at baseline (22% and 14%, respectively) and throu-
ghout treatment was higher among those who received 
ADT and radiotherapy compared to those treated with 
radiotherapy only (mean 35% and 17%, respectively)
[47]
. 
In a recent study, ADT was found to be related to in-
creased insomnia among 263 men with non-metastatic 
prostate cancer; with the highest prevalence at 39%, co-
inciding with the greatest exposure to ADT
[48]
.  
In contrast, in a randomised controlled trial of 347 
men who were recruited to the Scandinavian Prostate 
Cancer Group-4 trial and who received either radical 
prostatectomy or watchful waiting, 30%–40% of men 
in both treatment groups consistently had insomnia up to 
8 years post-treatment
[8]
.  
Are we sleeping on the job? Insomnia among men with prostate cancer 
80 
 doi: 10.18282/amor.v2.i2.94 
These studies demonstrate that while the prevalence 
of insomnia decreases post-treatment, insomnia is a 
chronic condition for many men with prostate cancer, 
which lasts long into survivorship
[8,14,18,21,25,42-49]
. 
Prevalence of insomnia among partners and 
spouses of men with prostate cancer 
One cross-sectional study investigated the prevalence of 
insomnia among spouses and/or partners of men with 
prostate cancer. In the US, Kornblith et al. reported in 
1994 that 37% of the 83 participating spouses experi-
enced insomnia or sleep disturbances, which was higher 
than that experienced by their partners with prostate 
cancer (29%)
[17]
. 
Insomnia and different cancer sites 
Insomnia is associated with different cancer sites to var-
iable degrees
[51]
. In studies directly comparing different 
cancer sites, the prevalence of insomnia was lower in 
men with prostate cancer than in women with breast 
cancer, as well as among men and women with colorectal, 
lung, head and neck cancers
[22,24,26]
. In contrast, the prev-
alence of insomnia syndrome was similar among men 
with localised prostate cancer (18%) and women 
with breast cancer (19%)
[42]
. 
Furthermore, among patients with advanced cancer, a 
diagnosis of prostate, breast, lung, and gastrointestinal 
cancer was associated with increased likelihood of in-
somnia
[28]
. Insomnia among prostate cancer patients was 
also reportedly higher than in the general population
[19]
. 
Risk factors for the development of insomnia 
among men with prostate cancer  
Within cancer populations, risk factors associated with 
insomnia have been categorised as: (i) predisposing fac-
tors (including increasing age, family and/or personal 
history, and high trait anxiety particularly the hyper-
arousability trait), (ii) precipitating factors (e.g., a stress-
ful event including cancer diagnosis, as well as disease 
factors, treatment symptoms and stress), and (iii) perpet-
uating factors (behavioural and cogitative factors), which 
contribute to the maintenance of insomnia
[51]
. 
Predisposing factors 
Age 
Unlike populations without cancer, insomnia is inversely 
related with age in patients with cancer at mixed 
sites
[21,23,28,44]
 and also among men with prostate can-
cer
[42,49]
. Younger men are also more likely to develop 
insomnia syndrome
[42]
, suggesting that younger men may 
have more trouble adjusting to their ‘new normality’ and 
consequently, are more susceptible to chronic sleeping 
difficulties.   
Marital status 
Unmarried men are at a higher risk of experiencing in-
somnia
[42,49]
. 
Psychological health and insomnia 
The relationship between psychological health and in-
somnia is not completely understood. Men with prostate 
cancer who experience poor psychological health in-
cluding anxiety, depression and distress more often ex-
perience insomnia
[8,21,42,44,49]
. For example, men with 
prostate cancer with high trait anxiety have been found to 
have a higher prevalence of insomnia
[42,49]
. There is also 
evidence of an increased risk of insomnia among men 
with depression
[42,44,49]
; 52% of prostate cancer patients 
with insomnia in one study had clinically significant de-
pression
[44]
. However, similar proportions of men with 
and without these negative emotional states experienced 
insomnia in another study
[42]
. Furthermore, insomnia is 
one of the symptoms observed to increase the risk of 
anxiety and depression among prostate cancer survi-
vors
[20]
. The relationship between depression, anxiety 
and distress on the development and maintenance of in-
somnia among men with prostate cancer may be bi-di-
rectional and requires further research.   
Different coping styles have been shown to predict 
sleeping patterns in patients with breast and prostate 
cancer. Avoidance coping is predictive of worse sleep, 
whereas approach coping is predictive of better sleep 
among men with prostate cancer (N = 23) who were 
treated with radiotherapy
[50]
. 
Personal history of insomnia 
Men with sleeping problems at diagnosis were more 
likely to consistently have sleeping problems throughout 
the cancer care trajectory
[8,24,25]
. 
Precipitating factors 
Cancer diagnosis 
Being diagnosed with cancer is a stressful event. In ret-
rospective studies, a high proportion of men reported that 
their insomnia coincided with their prostate cancer diag-
nosis
[21,24,25,42]
. One such study described that the onset of 
symptoms was secondary to prostate cancer diagnosis in 
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54% of men experiencing insomnia syndrome
[42]
. The 
majority of longitudinal studies described the highest 
prevalence of insomnia, or highest insomnia scores indi-
cating worse symptomology, at the time point closest to 
diagnosis
[23-25,49]
. In one longitudinal study, 15% of the 
men reported that their first episode of insomnia coin-
cided with their diagnosis
[24,25]
. In addition, in studies 
reporting on the differential effects of cancer stages on 
insomnia, a worse prognosis is a risk factor for insom-
nia
[42]
. 
Cancer treatment  
As described above, prostate cancer treatments have dif-
ferential effects on insomnia among patients and survi-
vors. In a large population-based study of 3,348 prostate 
cancer survivors, insomnia was experienced by men 
treated with ADT, radiotherapy, active surveillance/wa-
tchful waiting, radical prostatectomy and brachytherapy 
up to 18 years into survivorship
[14]
. However, insomnia 
was consistently reported to be higher in men treated 
with ADT or radiotherapy or a combination of these mo-
dalities
[14,25,44,45,47-50]
. 
The effects of various treatments on the initiation and 
maintenance of insomnia have been shown to be medi-
ated through the treatment side effects experienced by 
men with prostate cancer, particularly night sweats/hot 
flashes and nocturia
[27,28,42,45,47,48]
. An interaction between 
these symptoms has also been proposed whereby when 
men wake up due to night sweats, they also empty 
their bladder, thus prolonging the length of time they are 
awake at night
[47]
. Other common symptoms that have  
been shown to increase risk of insomnia are pain and 
intestinal problems
[42]
. While there is some evidence that 
men can adapt to the adverse effects of ADT on insom-
nia
[47]
, the management of insomnia may be improved by 
a greater use of interventions to treat the adverse effects 
experienced by men following their diagnosis of, and 
treatment for prostate cancer. 
Perpetuating factors 
New behaviours that begin following a cancer diagnosis 
and during treatment, including day time napping, sleep 
monitoring and unhelpful beliefs about sleep, all contrib-
ute to the maintenance of insomnia into survivorship
[42]
. 
Impact of insomnia on men with prostate 
cancer 
HRQoL 
In studies investigating the HRQoL of men with prostate 
cancer, insomnia is consistently the symptom that re-
ceives the highest score
[19]
 or one of the highest scores, 
indicating worse symptomology
[8,12,14,15,23,26]
. Higher 
symptomology is associated with lower HRQoL among 
men with prostate cancer into survivorship
[14]
. However, 
not all studies found that sleeping difficulties negatively 
affected general HRQoL
[17,47]
. Kornblith et al. found that 
pain, fatigue and urinary problems, but not insomnia, 
were associated with HRQoL among 172 prostate cancer 
patients
[17]
. Daytime fatigue and low energy have been 
commonly associated with insomnia among cancer pa-
tients, including men with prostate cancer
[21,27,32,44,47,49]
 
and are negatively associated with many HRQoL sub-
scales
[49]
.  
Insomnia and risk of prostate cancer mor-
tality 
There is some evidence that baseline HRQoL domains 
including insomnia are predictive of survival among men 
with prostate cancer
[12,13,22]
. Insomnia, as part of a symp-
tom cluster including pain and fatigue, is associated with 
more adverse outcomes in older cancer patients
[22]
. 
However, HRQoL domains did not add to the ability of 
predictive models which included biochemical and clin-
ical data
[13]
.   
A large prospective study of 305,057 men in the US 
found that neither insomnia nor work schedule (i.e., ro-
tating and fixed shifts) were associated with prostate 
cancer mortality over a 28-year follow-up
[52]
. However, 
the adjusted relative risk (RR) of fatal prostate cancer 
was significantly higher among men who slept for 3–5 h 
(RR 1.64, 95% confidence intervals (CI) 1.06, 2.54) and 
6 h (RR 1.28, 95% CI 0.98, 1.67) per night, compared to 
those who slept for 7 h per night during the first 8 years 
of follow-up. The authors suggested that a short sleep 
duration could affect the later stages of prostate carcino-
genesis. 
Management of insomnia among men with 
prostate cancer 
Pharmaceutical management of insomnia among men 
with prostate cancer was not uncommon, with between 
20% and 25% of cancer patients regularly take sleeping 
pills
[21,42,53,54]
. However, in many cases this management 
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is unsuccessful with levels of insomnia remaining 
high
[44,53]
. 
Behavioural therapy in the form of individualised 
sleep plans, stimulus control, relaxation training and 
sleep restriction have been used to manage insomnia in 
cancer populations
[55]
. However, cognitive behavioural 
therapy (CBT) aimed at changing beliefs and attitudes 
about insomnia in conjunction with behavioural therapy, 
is considered the gold standard, non-pharmaceutical 
management of insomnia. CBT has been found to suc-
cessfully improve many dimensions of insomnia includ-
ing increased sleep effectiveness, and reduced sleep 
latency, nocturnal awakenings and insomnia severity in 
cancer patients who received CBT compared to those 
who did not
[56-58]
. A recent systematic review concluded 
that the quality of the evidence supported a strong rec-
ommendation for the use of CBT among cancer survivors 
experiencing insomnia
[58]
. CBT interventions also had a 
positive effect on daytime fatigue, at least in the short 
term
[57]
. However, the majority of these studies have been 
undertaken among women with localised breast can-
cer
[55,56,58]
. 
Three randomised controlled trials (RCT) investigat-
ing the effect of CBT on insomnia included men with 
prostate cancer. Of these, Garland et al. included 8 men 
with prostate cancer (7% of total)
[59] 
and Ritterband et al. 
included 4 men
[60]
, but the cancer site was not identified 
and neither trial presented results specifically for men 
with prostate cancer. One RCT encompassed 150 patients 
with cancer at mixed sites including men with prostate 
cancer (N = 34; 23%) suffering from insomnia for at 
least 6 months
[53]
. This intervention involved 5 small 
group CBT sessions, which were delivered by an oncol-
ogy nurse with specialist training. This intervention was 
successful up to the final measurement time point 6 
months post-intervention, at reducing sleep latency and 
nocturnal awakenings, and at increasing sleep efficacy 
measured both subjectively and objectively. A mean re-
duction in insomnia symptoms of almost 1 h was ob-
served in the CBT group compared to the usual treatment 
group. More than half (51%) of the CBT arm achieved 
the criterion for normal sleep compared to 34% in the 
control group following treatment, but this difference 
was not observed at the 6-month follow-up. Those in the 
CBT group also had increased HRQoL outcomes, in-
cluding decreased fatigue, anxiety and depression 
post-treatment and at follow-up compared to the control 
group. However, results by cancer site were not reported; 
therefore, it is unknown whether this CBT intervention 
was effective in men with prostate cancer. 
Discussion 
This review illustrates that insomnia is common among 
men with prostate cancer, affecting 8%–53% of men 
during the cancer care trajectory, from diagnosis up to 18 
years post-diagnosis. However, studies investigating the 
prevalence of insomnia and/or factors associated with 
insomnia or sleep disturbances within this cancer popu-
lation were very heterogeneous with regard to the study 
design, instruments used to investigate insomnia preva-
lence and the age, cancer stage, treatment received, and 
time point during the cancer trajectory of the study par-
ticipants. In addition, many of the studies involved a 
relatively small number of participants. It is likely that 
these differences explain the wide variation in the preva-
lence of insomnia reported in this cancer group. It also 
makes it difficult to draw conclusions regarding risk fac-
tors for the development and maintenance of insomnia. 
Despite this, some trends are suggested. For many men, 
insomnia begins with their prostate cancer diagnosis. 
Younger men with prostate cancer are more likely to 
experience insomnia, which is contrary to those without 
cancer. This suggested that younger men may find it more 
difficult to adjust to their new normality
[61]
, which may 
involve multiple adverse effects from their prostate cancer 
diagnosis and/or its treatment including impotence, uri-
nary incontinence, bowel symptoms and fatigue. Fur-
thermore, younger men are more likely to have depen-
dents, mortgages and to be in employment. Their working 
life may be disrupted with long periods of sick leave 
and/or early retirement with consequent changes in their 
financial circumstances, all of which are associated with 
financial stress and strain among men with prostate can-
cer
[62]
. All of these factors can result in an altered self- 
image and changes in intimate relationships
[61]
.  
Men who received treatment were more likely to ex-
perience insomnia than those who were untreated, in-
cluding those with metastatic prostate cancer. Insomnia 
has been found to be high prior to surgery, and during 
treatment, especially during radiotherapy as well as ADT, 
with slight decreases in the prevalence of insomnia 
post-treatment. There is less information on the effect of 
other treatments, including brachytherapy, on insomnia. 
However, insomnia is also common during survivor-
ship
[14]
. The effects of various treatments on the initiation 
and maintenance of insomnia is likely to be mediated, at 
least in part, through the adverse effects of treatment. 
Two such common adverse effects, night sweats/hot fla-
shes and nocturia, cause night time waking
[27,28,42,45,47,48]
. 
These symptoms have also been proposed to have an 
additive effect whereby when men wake up due to night 
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sweats, they may also empty their bladder, thus prolong-
ing the length of time they are awake at night and possi-
bly making it more difficult to resume sleep
[47]
. Some 
men can adapt to the adverse effects of ADT
[47]
; however, 
the management of insomnia may be improved by treat-
ing adverse treatment side effects with greater use of 
interventions such as the cool pad pillow topper, which 
reduces the frequency/severity of hot flushes and sleep 
disturbance among women, and a greater use of inconti-
nence medication (e.g., tolterodine)
[47,63]
.   
Men with a personal and/or family history of insomnia, 
those who experience distress, anxiety and/or depression, 
and men with later stages of cancer are at an increased 
risk of insomnia. The spouses/partners of these men may 
also be at a higher risk of insomnia; however, its preva-
lence will have to be investigated further. More research 
into the risk factors of insomnia is required, along with 
the effects of insomnia on cancer outcomes, where trends 
towards worse outcomes were observed among men with 
prostate cancer who experience insomnia.  
Currently, up to one-quarter of men with prostate 
cancer who experience insomnia are being managed 
pharmacologically, but this is not necessarily effective as 
evidenced by the persistent high levels of insomnia. CBT 
has been shown to effectively manage insomnia in some 
cancer populations. However, despite the high incidence 
and prevalence of prostate cancer, there is a dearth of 
research into the management of insomnia in this cancer 
population. Development of interventions to manage this 
distressing symptom is required.   
Conclusion 
Insomnia is common among men with prostate cancer 
undergoing treatment and also into survivorship. More 
than 20% of men with prostate cancer who experience 
insomnia are prescribed hypnotic medication. Prostate 
cancer treatment modalities have differential effects on 
insomnia; men treated with ADT experience the highest 
prevalence of insomnia but the incidence is also high 
among those who receive radiotherapy. Those most at risk 
include men with a history of insomnia, younger men, 
unmarried men, and those experiencing adverse effects 
(particularly night sweats and urinary problems such as 
nocturia) following their diagnosis and treatment. In-
somnia is associated with lower HRQoL and has negative 
effects on the psychological health of survivors. CBT 
has been shown to successfully manage cancer-related 
insomnia in women with breast cancer. However, despite 
the burden of prostate cancer to men, research into the 
management of insomnia among men with prostate cancer 
is lacking. Increased use of interventions to manage 
treatment side effects and the development of CBT in-
terventions to manage insomnia are necessary to address 
insomnia in this large cancer population. This in turn may 
lead to an improvement in the HRQoL and psychological 
health of men with prostate cancer into survivorship. 
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